Table 5 Treatment-related adverse events in HCC patients with Lenvatinib based combination treatment
Adverse Event | Any Grade | Grade I–II | Grade III–V |
|---|---|---|---|
Any adverse event | 68/94.4% | 49/68.5% | 19/26.3% |
Rash | 7/9.7% | 7/9.7% | 0/0.00% |
Diarrhea | 13/18.1% | 10/13.9% | 3/4.2% |
Anemia | 23/31.9% | 16/22.2% | 7/9.7% |
Elevate transaminase | 28/38.9% | 21/29.2% | 7/9.7% |
Hypertension | 11/15.3% | 8/11.1% | 3/4.2% |
Leukopenia | 16/22.2% | 12/16.7% | 4/5.6% |
Thyroid dysfunction | 13/18.1% | 13/18.1% | 0/0.00% |
Constipation | 4/5.6% | 4/5.6% | 0/0.00% |
Bleeding | 8/11.1% | 8/11.1% | 0/0.00% |
Vision loss | 1/1.4% | 1/1.4% | 0/0.00% |
Proteinuria | 25/34.7% | 25/34.7% | 0/0.00% |
Fever | 2/2.8% | 2/2.8% | 0/0.00% |
Fatigue | 9/12.5% | 9/12.5% | 0/0.00% |
Hand-foot skin reaction | 10/13.9% | 10/13.9% | 0/0.00% |
Decreased appetite | 4/5.6% | 4/5.6% | 0/0.00% |
Vomitting | 3/4.2% | 3/4.2% | 0/0.00% |
Bloody stools | 1/1.4% | 1/1.4% | 0/0.00% |